Related Party Transactions	12 Months Ended
Dec. 31, 2021
Related Party Transactions [Abstract]
Related Party Transactions	(8) Related Party Transactions MPM Capital is a significant investor in the Company through one of its managed funds. In October 2016, the Company also began receiving consulting and management services pursuant to agreements with a managing director at MPM Capital and a principal at F2 Ventures, also a significant investor in the Company. No expenses were incurred for the year ended December 31, 2021. For the year ended December 31, 2020, the Company incurred $0.2 million for management and advisory services, inclusive of their director compensation, in connection with those agreements. For each of the years ended December 31, 2021 and 2020, the Company paid MPM Capital less than $0.1 million for other operational support. These expenses were recorded as general and administrative expense. In April 2020, the Company entered into a consulting agreement (the Globeways Agreement) with Globeways Holdings Limited, or Globeways. Globeways and entities affiliated with F2 Ventures beneficially own in the aggregate greater than five percent of the Company’s outstanding shares and Globeways is beneficially owned by a member of the Company's board of directors. Pursuant to the Globeways Agreement, the board member provides leadership and advice regarding the Company’s scientific, clinical, product development and related activities and operations. Pursuant to the Globeways Agreement, the Company pays Globeways a consulting fee at a monthly rate of $25,000. As the sole beneficial owner of Globeways, this board member receives all of the compensation paid to Globeways under the Globeways Agreements. For the years ended December 31, 2021 and 2020, the Company incurred less than $0.1 million and $0.2 million in costs related to this agreement, respectively. The agreement expired as of March 31, 2021. Royalty Transfer Agreements Between October 2019 and May 2020, each of the Asset Subsidiaries entered into royalty transfer agreements with MPM Oncology Charitable Foundation, Inc. and UBS Optimus Foundation (together, the Foundations). Under each of these respective agreements, each Foundation is entitled to receive a royalty equal to 0.5% (1.0% in aggregate) of all global net sales of any products developed by the applicable subsidiary, subject to limitations after patent expirations and on intellectual property developed after a change of control. The Company has deemed these royalty transfer agreements to be freestanding financial instruments that should be accounted for at fair value. Management of the Company has concluded that these instruments had no value at the inception of the agreements and at December 31, 2021 and 2020. Given the early-stage nature of the underlying technologies and inherent technical, regulatory and competitive risks associated with achieving approval and commercialization, the Company ascribed no value to the royalty transfer agreements as of December 31, 2021 and 2020. The Company currently does not have any applicable net sales from its products and as a result, has paid no royalties under these obligation as of December 31, 2021 and 2020 nor has the Company accrued any liability as of such dates. The Company will monitor these instruments for changes in fair value at each reporting date

Related Party Transactions

12 Months Ended

Dec. 31, 2021

(8)

Related Party Transactions

MPM Capital is a significant investor in the Company through one of its managed funds. In October 2016, the Company also began receiving consulting and management services pursuant to agreements with a managing director at MPM Capital and a principal at F2 Ventures, also a significant investor in the Company. No expenses were incurred for the year ended December 31, 2021. For the year ended December 31, 2020, the Company incurred $0.2 million for management and advisory services, inclusive of their director compensation, in connection with those agreements.

For each of the years ended December 31, 2021 and 2020, the Company paid MPM Capital less than $0.1 million for other operational support. These expenses were recorded as general and administrative expense.

In April 2020, the Company entered into a consulting agreement (the Globeways Agreement) with Globeways Holdings Limited, or Globeways. Globeways and entities affiliated with F2 Ventures beneficially own in the aggregate greater than five percent of the Company’s outstanding shares and Globeways is beneficially owned by a member of the Company's board of directors. Pursuant to the Globeways Agreement, the board member provides leadership and advice regarding the Company’s scientific, clinical, product development and related activities and operations. Pursuant to the Globeways Agreement, the Company pays Globeways a consulting fee at a monthly rate of $25,000. As the sole beneficial owner of Globeways, this board member receives all of the compensation paid to Globeways under the Globeways Agreements.

For the years ended December 31, 2021 and 2020, the Company incurred less than $0.1 million and $0.2 million in costs related to this agreement, respectively. The agreement expired as of March 31, 2021.

Royalty Transfer Agreements

Between October 2019 and May 2020, each of the Asset Subsidiaries entered into royalty transfer agreements with MPM Oncology Charitable Foundation, Inc. and UBS Optimus Foundation (together, the Foundations). Under each of these respective agreements, each Foundation is entitled to receive a royalty equal to 0.5% (1.0% in aggregate) of all global net sales of any products developed by the applicable subsidiary, subject to limitations after patent expirations and on intellectual property developed after a change of control. The Company has deemed these royalty transfer agreements to be freestanding financial instruments that should be accounted for at fair value. Management of the Company has concluded that these instruments had no value at the inception of the agreements and at December 31, 2021 and 2020.

Given the early-stage nature of the underlying technologies and inherent technical, regulatory and competitive risks associated with achieving approval and commercialization, the Company ascribed no value to the royalty transfer agreements as of December 31, 2021 and 2020. The Company currently does not have any applicable net sales from its products and as a result, has paid no royalties under these obligation as of December 31, 2021 and 2020 nor has the Company accrued any liability as of such dates. The Company will monitor these instruments for changes in fair value at each reporting date